Lists of differentially expressed genes and gene ontology (GO) enrichment analysis under ambient versus high night-time temperatures with 1-MCP application. by Wardah K. Mustahsan (17484456)

Venn diagrams of the number of DEGs between each comparison. by Wardah K. Mustahsan (17484456)

Temporal distribution of HFMD incidence in Guangzhou from 2013 to 2023. by Haipeng Luo (5322419)

Effect of variety on physiological traits under ambient night-time temperature (ANT) and high night-time temperature (HNT) conditions, with or without MCP (1-methylcyclopropene) tr... by Wardah K. Mustahsan (17484456)

Changes in the liver fibrosis-related markers in breast cancer patients with a FIB-4 index of >2.30 during letrozole treatment. by Kazuyoshi Ohkawa (836847)

Gender-specific incidence trends of HFMD in Guangzhou from 2013 to 2023. by Haipeng Luo (5322419)

Changes in the FIB-4 index in breast cancer patients with a FIB-4 index of ≥ 2.67 during letrozole and anastrozole treatment. by Kazuyoshi Ohkawa (836847)

Changes in the liver fibrosis-related markers in breast cancer patients with a FIB-4 index of >2.30 during anastrozole treatment. by Kazuyoshi Ohkawa (836847)

Flowchart of patient selection in this study. by Kazuyoshi Ohkawa (836847)

S1 Data - by Kazuyoshi Ohkawa (836847)

Preoperative background characteristics of the patients. by Yasuyuki Sotani (20114144)

Loss of life expectancy that would result if colorectal cancer missed in 2011 had been diagnosed in 2011 (unit: years). by Hiroaki Saito (24514)

Loss of life expectancy by age group and stage of colorectal cancer and change if detected after one year. by Hiroaki Saito (24514)

Estimated distribution of colorectal cancer stage among patients assumed to have missed diagnosis in 2011 (unit: persons). by Hiroaki Saito (24514)

Annual treatment frequencies in all eyes. by Yasuyuki Sotani (20114144)

“…<p>The number of anti-VEGF treatments, STTA, MA-PC, PPV, and total treatments (mean ± SD) significantly decreased from 2.6 ± 1.6, 0.3 ± 0.8, 0.6 ± 0.8, 0.1 ± 0.3, and 3.7 ± 1.7 preoperatively to 0.8 ± 1.9, 0.0 ± 0.2, 0.3 ± 1.0, 0.0, and 1.2 ± 2.2; at year 2 to 0.7 ± 2.0, 0.1 ± 0.6, 0.0 ± 0.2, 0.0 ± 0.2, and 1.0 ± 2.1; and at year 3 to 0.9 ± 2.2, 0.0, 0.2 ± 1.0, 0.0 ± 0.2, and 1.1 ± 3.1 (Kruskal–Wallis test, P < 0.001; Dunn’s test, **P < 0.01). …”

Estimated detected and non-detected colorectal cancer rates and their clinical stages based on colorectal cancer screening in Minamisoma City in 2011. by Hiroaki Saito (24514)

Additional loss of life expectancy and cost per life-year saved resulting from changes in colorectal cancer stage due to a 1-year diagnostic delay. by Hiroaki Saito (24514)

Time course of central retinal thickness (CRT) in all eyes. by Yasuyuki Sotani (20114144)

“…<p>Mean CRT (μm ± standard deviation) significantly decreased from 504.7 ± 118.2 μm preoperatively to 302.5 ± 60.5 at 1 month, 307.5 ± 64.4 at 3 months, 286.8 ± 49.0 at 6 months, 305.3 ± 79.5 at 12 months, 288.8 ± 79.1 at 24 months, and 295.2 ± 87.4 at 36 months (Kruskal–Wallis test, P < 0.001; Dunn’s test, **P < 0.01). …”

Conceptual diagram of survival curve and loss of life expectancy. by Hiroaki Saito (24514)

Time course of central retinal thickness (CRT) in recurrence and non-recurrence groups. by Yasuyuki Sotani (20114144)

“…Regarding the mean number of treatments in the recurrence group, anti-VEGF, STTA, MA-PC, PPV, and total treatment counts in the year before surgery were 3.0 ± 1.4, 0.1 ± 0.3, 0.8 ± 1.0, 0.1 ± 0.3, and 4.0 ± 2.1, respectively. These values significantly decreased in the first postoperative year to 2.3 ± 2.6, 0.1 ± 0.3, 0.8 ± 1.6, 0, and 3.1 ± 2.8; in the second year to 2.1 ± 2.8, 0.4 ± 1.0, 0.0, 0.1 ± 0.3, and 2.6 ± 2.8; and in the third year to 2.0 ± 2.2, 0, 0.6 ± 1.7, 0.1 ± 0.3, and 2.8 ± 3.5 (Kruskal–Wallis test, p < 0.001; <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0332941#pone.0332941.g007" target="_blank">Fig 7</a>). …”